Ankylosing spondylitis-related secondary amyloidosis responded well to etanercept: a report of three patients


Kobak S., Oksel F. , Kabasakal Y. , Doğanavşargil E.

CLINICAL RHEUMATOLOGY, vol.26, no.12, pp.2191-2194, 2007 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 26 Issue: 12
  • Publication Date: 2007
  • Doi Number: 10.1007/s10067-007-0679-x
  • Title of Journal : CLINICAL RHEUMATOLOGY
  • Page Numbers: pp.2191-2194

Abstract

Secondary (AA) amyloidosis is one of the most significant complications of ankylosing spondylitis (AS) that frequently leads to proteinuria and renal dysfunction. Anti-tumor necrosis factor alpha (anti-TNF) agents are promising in inducing clinical remission by suppressing systemic inflammation in AA amyloidosis. We report three cases with AS-related AA amyloidosis that responded well to etanercept therapy. Despite treatment with disease modifying anti-rheumatic drugs, all three patients had active AS, marked proteinuria, impaired renal function, and low serum albumin level. During 1-year treatment with etanercept, all patients experienced gradual improvement in all of these parameters.